RVVC
Conditions
Interventions
Case series:Nil
Sponsors
The Fifth Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. RVVC group (1) Meet the above diagnostic criteria; (2) Female, aged 20-49, married or having sex life, with regular and normal menstrual cycles; (3) At least 2 or more symptoms or signs of VVC, 4 or more episodes of VVC in the past year; (4) No antibiotics and probiotics were used in the two weeks before selection; (5) Those who voluntarily participate and sign the informed consent; 2. VVC group (1) Meet the above diagnostic criteria; (2) Female, aged 20-49, married or having sex life, with regular and normal menstrual cycles. (3) Vaginal secretion examination: Candida positive, at least 2 or more VVC symptoms or signs, no history of VVC attack in the past 1 year. (4) No antibiotics and probiotics were used in the two weeks before selection. (5) Those who voluntarily participate and sign the informed consent. (3. Normal control group (1) Female, aged 20-49, married or having sex life, with regular and normal menstrual cycles; (2) According to the principle of randomness and balance, select normal non-pregnant women; (3) Examination of vaginal discharge: negative; (4) No antibiotics and probiotics were used in the two weeks before selection; (5) Those who voluntarily participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Women during pregnancy and lactation; 2. Patients suffering from diabetes and oral contraceptives; 3. Patients with severe disease of the heart, liver, kidney and other major organs, hematopoietic diseases and tumors who cannot guarantee the smooth progress of this study; 4. Those who are unable to cooperate, such as those who have a history of neurological and mental illness or are unwilling to cooperate; 5. Those who have received systemic antifungal treatment within 3 months or have received topical antifungal treatment within 1 month; 6. Those who have immunological diseases or are taking immunosuppressants or regulators, or those who have been vaccinated one year before joining the group; 7. Mixed vaginal infection: such as mixed trichomoniasis, bacterial vaginitis, mycoplasma, chlamydia infection; 8. Subjects who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vaginal microecology morphology and function; | — |
Contacts
Public ContactRuan Lijun
The Fifth Affiliated Hospital of Southern Medical University
Outcome results
None listed